MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
ANPC - AnPac Bio-Medical Science Co Ltd
$1.70
-0.05(-2.86%)6:00:00 PM 11/26/2021
Anpac Bio-Medical Science Co., Ltd., a development-stage biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests to corporations and life insurance companies in the People's Republic of China and the United States. It also manufactures cancer differentiation analysis devices; and offers physical checkup package services. The company was founded in 2010 and is headquartered in Lishui, the People's Republic of China.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

No summary
Related Topics

Stock news

    11/26/2021ANPC
    AnPac Bio Reports Nine Months Ended September 30, 2021, Same Period Achieved Record Revenue Increased By 55.3% While Non-GAAP Net Loss Reduced by 6.8%

    PHILADELPHIA, Nov. 26, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, announced today its unaudited financial results for the nine months ended September 30, 2021. The Company's financial statements and related financial information for the quarter ended September 30, 2021 are unaudited and have not been reviewed by the Company's independent registered accoun

    11/11/2021ANPC
    CORRECTION -- Anpac Bio, USA

    PHILADELPHIA, Nov. 11, 2021 (GLOBE NEWSWIRE) -- In its press release dated November 9, 2021 entitled “AnPac Bio Announces Pricing of Approximately $2.9 Million Underwritten Public Offering of American Depositary Shares”, the dollar size of the offering and the number of American Depositary Shares being sold included the exercise of the over-allotment option rather than just the base offering. The expected closing date has been corrected to be November 15, 2021. A corrective press release is belo

    11/10/2021ANPC
    AnPac Bio Announces Pricing of Approximately $2.9 Million Underwritten Public Offering of American Depositary Shares

    PHILADELPHIA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC, the “Company”), a biotechnology company with operations in China and the United States focusing on early cancer screening and detection, today announced the pricing of an underwritten public offering of 1,301,928 of its American Depositary Shares (“ADSs”) at a public offering price of $2.22 per share, for gross proceeds to the Company of approximately $2.9 million, before deducting the underwriting

    11/9/2021ANPC
    UPDATE - AnPac Bio Commences Proposed Public Offering of American Depositary Shares

    PHILADELPHIA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC, the “Company”), a biotechnology company with operations in China and the United States focusing on early cancer screening and detection, today announced it has commenced an underwritten public offering of its American Depositary Shares (“ADSs”). EF Hutton, division of Benchmark Investments, LLC, is acting as the sole book-running manager for the offering. The offering is subject to market and other

    11/9/2021ANPC
    AnPac Bio Commences Proposed Public Offering of American Depositary Shares

    SUNRISE, Fla., Nov. 09, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC, the “Company”), a biotechnology company with operations in China and the United States focusing on early cancer screening and detection, today announced it has commenced an underwritten public offering of its American Depositary Shares (“ADSs”). EF Hutton, division of Benchmark Investments, LLC, is acting as the sole book-running manager for the offering. The offering is subject to market and othe

    11/8/2021ANPC
    Anpac Bio Invites You to Join Us at the Q4 Virtual Investor Summit

    Philadelphia, Pennsylvania--(Newsfile Corp. - November 8, 2021) - Anpac Bio (NASDAQ: ANPC) today announced that Phil Case, Head of Investor Relations | PR will be attending the Q4 Virtual Investor Summit. Learn how Anpac Bio is democratizing early cancer screening and detection. Current methods for early cancer screening and detection have limited clinical utility and average to non-existent performance for early cancer screening and detection, which is critical for reducing cancer related morta

    10/22/2021ANPC
    AnPac Bio-Medical Science Co. Ltd.'s Unique Platform Offering Comprehensive Blood Test Data, New Approach to Disease Screening

    AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, has developed the Cancer Differentiation Analysis (“CDA”) technology — a proprietary approach to detect cancerous and pre-cancerous diseases. “CDA uses the blood’s natural biophysical properties to identify cancerous environments before tumors even form. The CDA platform, in which technology is combined with protein-based biomarker tests to obtain even more comprehensive information, can be used to